For the third quarter of 2026, analysts expect IQVIA Holdings Inc to report consensus revenue of $4.37 billion and earnings per share of $2.94, while the current stock price of $279.36 remains below the average analyst price target of $299.11.
Investors are primarily focused on the Research & Development Solutions segment's net new bookings and book-to-bill ratio to gauge the recovery of clinical trial demand from biopharma clients.
Sentiment is bolstered by the company's expanded partnership with Veeva and the rapid deployment of over 290 AI agents to improve operational efficiency. However, macro headwinds in emerging biopharma spending and high debt leverage remain key watchpoints for the market.